WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 15, 517-523. Review Article ISSN 2277–7105

COST MINIMIZATION ANALYSIS OF ANTIBIOTICS AND ANTACIDS: A COMPREHENSIVE REVIEW

***Sreenu Thalla, M. Anusha, K. Blessi, T. Jayanthi, P. Siva Krishna, P. Srinivasa Babu**

Department of Pharmacology, Vignan Pharmacy College (Autonomous), Vadlamudi, Guntur, Andhra Pradesh, India – 522213.

Article Received on 28 June 2026,
Article Revised on 18 July 2026,
Article Published on 01 Aug. 2026,

https://doi.org/10.5281/zenodo.21674791

***Corresponding Author**

Sreenu Thalla

Department of Pharmacology, Vignan Pharmacy College (Autonomous), Vadlamudi, Guntur, Andhra Pradesh, India - 522213.

How to cite this Article: *Sreenu Thalla, M. Anusha, K. Blessi, T. Jayanthi, P. Siva Krishna, P. Srinivasa Babu. (2026). Cost Minimization Analysis of Antibiotics And Antacids: A Comprehensive Review. World Journal of Pharmaceutical Research, 15(15), 517–523.

ABSTRACT

Cost Minimization Analysis (CMA) is a pharmacoeconomic evaluation technique used to compare the costs of therapeutic interventions that have demonstrated equivalent clinical efficacy and safety. Antibiotics and antacids are among the most frequently prescribed medications worldwide and contribute significantly to healthcare expenditure. Given the availability of multiple generic formulations and therapeutic alternatives within these drug classes, CMA provides valuable information for selecting the most economical treatment option without compromising therapeutic outcomes. This review discusses the principles of CMA, its methodology, applications in antibiotics and antacids, factors influencing drug costs, current evidence from published studies, limitations, and future perspectives. The review highlights that generic substitution, rational prescribing, antimicrobial stewardship, and evidence -based procurement policies can substantially reduce healthcare costs while maintaining quality patient care.

KEYWORDS: Cost minimization analysis, Pharmacoeconomics, Antibiotics, Antacids, Generic medicines, Healthcare costs, Rational prescribing.

INTRODUCTION

Healthcare expenditures have increased dramatically over the past few decades due to rising disease burden, increasing drug prices, technological advances, and aging populations.

Pharmacoeconomics has emerged as an essential discipline that evaluates the economic impact of pharmaceutical interventions while maintaining clinical effectiveness.[1] Among pharmacoeconomic methods, Cost Minimization Analysis (CMA) is the simplest economic evaluation. CMA assumes that the interventions being compared have equivalent clinical efficacy and safety, making cost the sole criterion for decision-making.

Antibiotics and antacids are ideal candidates for CMA because numerous therapeutically equivalent brands are available, generic formulations dominate the market, large variations exist in acquisition costs. They are commonly prescribed in both outpatient and inpatient settings. They contribute significantly to national pharmaceutical expenditure.[2]

Pharmacoeconomics: An Overview

Pharmacoeconomics evaluates both costs and outcomes associated with pharmaceutical products. Major pharmacoeconomic methods include:

Method	Outcome Measured
Cost-Minimization Analysis	Costs only
Cost-Effectiveness Analysis	Natural units
Cost-Utility Analysis	Quality-adjusted life years (QALYs)
Cost-Benefit Analysis	Monetary values
Cost-Consequence Analysis	Multiple outcomes

CMA is appropriate only when treatments have demonstrated therapeutic equivalence through high-quality clinical evidence.[3]

Cost Minimization Analysis

Cost Minimization Analysis is an economic evaluation that compares the costs of two or more interventions with proven equivalent clinical outcomes. To identify the least expensive treatment option without compromising efficacy or safety. Define therapeutic alternatives, establish clinical equivalence, identify relevant costs, Measure resource utilization, Calculate total treatment costs, perform sensitivity analysis, Draw conclusions.[4]

Types of Costs

Direct Medical Costs: Drug acquisition, Laboratory investigations, Hospitalization, Physician consultations, Nursing care.

Direct Non-medical Costs: Transportation, Caregiver expenses, Accommodation.

Indirect Costs: Productivity loss, Work absenteeism.

Intangible Costs: Pain, Anxiety, Reduced quality of life. In classical CMA, emphasis is

usually placed on direct medical costs.[5]

Cost Components in Antibiotic Therapy

Antibiotic treatment involves several cost elements. Drug Costs like Brand price, Generic price, Dosage strength, Duration. Hospital Costs like Bed charges, ICU stay, Isolation.

Diagnostic Costs like Blood culture, Urine culture, Sensitivity testing. Monitoring Costs like liver function tests, kidney function tests, drug level monitoring. Adverse Event Costs like allergic reactions, drug-induced nephrotoxicity, *Clostridioides difficile* infection.[6]

Cost Components in Antacid Therapy

Treatment costs include Medication acquisition, Physician visits, Endoscopy (if required), Diagnostic investigations, Long-term maintenance therapy. Patients with chronic GERD often require prolonged therapy, increasing cumulative treatment costs.[7]

Antibiotics Suitable for Cost Minimization Analysis

Drug A	Drug B	Indication
Amoxicillin	Generic Amoxicillin	Respiratory infection
Cefixime	Generic Cefixime	UTI
Ciprofloxacin	Generic Ciprofloxacin	Gastroenteritis
Azithromycin	Generic Azithromycin	URTI
Metronidazole	Generic Metronidazole	Anaerobic infection

When bioequivalence has been established, generic versions usually provide identical clinical outcomes.

Antacids Suitable for Cost Minimization Analysis

Brand	Generic
Omeprazole	Generic Omeprazole
Pantoprazole	Generic Pantoprazole
Rabeprazole	Generic Rabeprazole
Esomeprazole	Generic Esomeprazole
Aluminum hydroxide suspension	Generic equivalent

Methodology for Cost Calculation

The total treatment cost may be estimated using

Total Cost = Drug Cost + Diagnostic Cost + Hospital Cost + Monitoring Cost + Adverse Event Cost

Example:

Brand antibiotic therapy= Drug cost = ₹600 + Laboratory = ₹300 + Consultation = ₹200

Total = ₹1100

Generic antibiotic therapy = Drug cost = ₹180 + Laboratory = ₹300 + Consultation = ₹200

Total = ₹680

Savings = ₹420. Clinical outcomes remain identical.

Applications of CMA in Antibiotics

Community-acquired pneumonia: Generic amoxicillin versus branded amoxicillin

Urinary tract infection: Generic nitrofurantoin versus branded nitrofurantoin

Skin infections: Generic cephalexin versus branded cephalexin

Surgical prophylaxis: Generic cefazolin versus branded cefazolin

These comparisons consistently demonstrate substantial savings through generic substitution[8]

Applications in Antacids

Examples include:

- Pantoprazole brands
- Omeprazole generics
- Rabeprazole formulations
- Aluminum hydroxide preparations

Because proton pump inhibitors demonstrate similar acid suppression when bioequivalent, CMA is frequently applicable.[9]

Evidence from Published Literature

Several studies have shown Generic antibiotics reduce treatment costs by 30–80%. Hospital antibiotic stewardship programs decrease antibiotic expenditure without adversely affecting patient outcomes. Generic proton pump inhibitors provide similar efficacy with significantly lower acquisition costs. Bulk procurement programs reduce institutional pharmaceutical expenditure.[10]

Factors Affecting Drug Costs

Drug-related: Brand, Patent status, Manufacturing cost, Packaging, Patient-related: Age, Renal function, Duration of therapy, Compliance. Healthcare System: Procurement policy, Insurance coverage, Government regulation.

Generic Medicines and Cost Savings

Generic medicines Demonstrate bioequivalence, meet regulatory quality standards, Have lower acquisition costs, improve patient affordability, Increase medication adherence. Numerous studies report savings ranging from 40% to 90% following generic substitution.[11]

Role of Antibiotic Stewardship

Antibiotic stewardship programs for reduce inappropriate prescriptions, promote narrow-spectrum antibiotics, shorten therapy duration, reduce antimicrobial resistance, lower hospital expenditure. These interventions improve both clinical and economic outcomes.[12]

Role of Hospital Formularies

Hospitals employ CMA when selecting formulary drugs by considering therapeutic equivalence, acquisition cost, storage requirements, supply reliability, prescribing frequency.[13]

Advantages of Cost Minimization Analysis

Simple methodology, easy interpretation, supports formulary decisions, encourages rational prescribing, promotes generic substitution, reduces healthcare expenditure.[14]

Limitations of Cost Minimization Analysis

Requires proven therapeutic equivalence, ignores differences in quality of life, not suitable when efficacy differs, may overlook indirect costs, cannot compare treatments with different safety profiles.

Future Perspectives

Future developments include integration of real-world evidence, AI-assisted pharmacoeconomic modelling, personalized medicine approaches, national electronic procurement systems, dynamic pricing strategies, Expanded antimicrobial stewardship initiatives.

CONCLUSION

Cost Minimization Analysis remains an important pharmacoeconomic tool for selecting among therapeutically equivalent antibiotics and antacids. With increasing healthcare costs and the widespread availability of generic medicines, CMA supports evidence-based, cost-conscious prescribing while maintaining clinical effectiveness. Generic substitution, antimicrobial stewardship, and rational formulary management can substantially reduce

pharmaceutical expenditures for healthcare systems and patients. However, CMA should only be applied when robust evidence confirms equivalent efficacy and safety. As healthcare systems continue to emphasize value-based care, CMA will remain a key component of drug policy, procurement, and clinical decision-making.

REFERENCES

1. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. 4th ed. Oxford: Oxford University Press, 2015.
2. Bootman JL, Townsend RJ, McGhan WF. *Principles of Pharmacoeconomics*. 3rd ed. Cincinnati: Harvey Whitney Books, 2005.
3. World Health Organization. *WHO guideline on country pharmaceutical pricing policies*. Geneva: WHO, 2020.
4. World Health Organization. *The Selection and Use of Essential Medicines*. Geneva: WHO, 2023.
5. ISPOR Task Force. Pharmacoeconomic guidelines around the world. *Value Health*, 2021; 24(1): 4–9.
6. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. *Cost-Effectiveness in Health and Medicine*. 2nd ed. Oxford: Oxford University Press, 2016.
7. National Institute for Health and Care Excellence (NICE). *Guide to the Methods of Technology Appraisal*. London: NICE, 2022.
8. American Society of Health-System Pharmacists. ASHP guidelines on formulary management. *Am J Health Syst Pharm*., 2020; 77(6): 450–461.
9. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for antimicrobial stewardship. *Clin Infect Dis*., 2007; 44(2): 159–177.
10. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? *Clin Microbiol Infect*, 2017; 23(11): 793–798.
11. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients' perceptions of generic medications. *Health Aff*., 2009; 28(2): 546–556.
12. Dunne SS, Shannon B, Dunne CP, Cullen W. Patient perceptions of generic medicines: A systematic review. *BMJ Open*, 2014; 4: e005564.
13. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs. *JAMA*, 2008; 300(21): 2514–2526.

14. Wouters OJ, Kanavos PG, McKee M. Comparing generic medicine policies internationally. *BMJ Glob Health*, 2017; 2: e000507.